arm in Biological Technology

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

... in the 150 mcg corifollitropin alfa treatment arm (38.9 percent per started cycle) was similar to ... in the 150 mcg corifollitropin alfa treatment arm (38.9 percent per started cycle) was similar to ... 3.4 percent in the corifollitropin alfa treatment arm versus 1.6 percent in the rFSH treatment ...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

... of death when compared to the control arm for patients receiving 6 or less cycles ... results in favor of the OGX-011 treatment arm in this trial are a clear indication that Phase 3 ... below. - The OGX-011 plus docetaxel arm met the primary endpoint of the trial ...

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

... chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard ... with no patients in the standard chemotherapy arm achieving a confirmed complete remission. ... frequent in the pixantrone than in the control arm (1.5% vs. 13.4%). CTI will be presenting ...

Video: Turning Hope Into Reality - VA Research to Restore Veterans' Abilities

... is launching a three-year study of an artificial arm that allows those who have lost their limb to ... health care system. "The advanced prosthetic arm is a high-tech example of how VA researchers are ... three-year "optimization study" of the artificial arm is the first large-scale clinical trial to play ...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... was 27.5 months for the patients in the OGX-011 arm and 16.9 months for those in the control ... indicate that patients in the OGX-011 arm have a death rate of approximately 40% ... before a mature median survival for the OGX-011 arm can be reported; however, based on the ...

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER

... may be provided to patients in either arm at the discretion of the physician. The design ... by data presented at ASCO 2008 from the Canadian arm of a fully recruited lead-in Phase I trial ... was 91.6% for the nimotuzumab plus radiation arm compared to 44.4% for the radiation alone arm. At ...

OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

... survival advantage observed in the OGX-011 arm represents an increase over the median survival ... two-month improvement in survival in the OGX-011 arm as compared to the control arm. All milestone ... was 27.5 months for the patients in the OGX-011 arm and 16.9 months for those in the control arm. ...

Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer

... (PFS) was 5.6 months on the Telcyta plus PLD arm compared to 3.7 months on the PLD control arm, p ... complete response (CR) for the Telcyta plus PLD arm and 8% for the PLD control arm. Of the 125 ... including 40 patients on the Telcyta plus PLD arm and 35 patients on the PLD control arm. The ...

Scientists restore movement to paralyzed limbs through artificial brain-muscle connections

... artificial stimulation directly to paralyzed arm muscles in order to drive arm movementa technique called functional electrical ... with real-time control of FES. "A robotic arm would be better for someone whose ...

RTXC Kernel Awareness Module from Quadros Systems Now Available for Keil Vision Debugger

... tool. The µVision IDE from Keil, an arm company, combines project management, make ... logo are trademarks of Quadros Systems, Inc. arm and RealView are registered trademarks of arm Limited. ARM7, ARM9, Cortex and Keil are ...

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia

... vs. 26.2%). Further, patients in the 800 mg arm achieved MMR significantly faster than those ... Ph+ cells) at 12 months. Patients in the 800 mg arm achieved complete cytogenetic response (CCyR) ... adverse events were 5.6% and 1.3% in the 800 mg arm and 400 mg arm, respectively. The 800 mg/day dose ...

Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones

... study to include a 600 mg celgosivir combination arm (600 mg celgosivir combined with the ... the 400 mg celgosivir combination treatment arm and the standard of care treatment arm. In ... the decision to stop the 600 mg combination arm of the study at this time was made based on the ...

Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History

... 25, 2008, enrollment in the Destination Therapy arm was 479 patients, an increase of 53 patients over ... Enrollment in the randomized portion of the DT arm of the trial was 291 patients, versus 265 ... be complete in May 2009. Enrollment in the BTT arm of the trial was 439 patients, compared with 390 ...

MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study

... will add a 600mg celgosivir combination therapy arm to its currently enrolling Phase II viral ... approvals. The purpose of this new treatment arm is to assess 600mg celgosivir (an oral alpha ... for the addition of a 600mg once daily dosing arm and the flexibility to increase the total number ...

Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial

... The trial is a multi-center, open label, two arm Phase 2 study for up to 80 patients who have ... benefit from prior docetaxel therapy enrolled in arm 1 of the trial, and three patients who had no response to prior docetaxel therapy enrolled in arm 2 of the study. The two patients ...

U-M research: New plastic is strong as steel, transparent

... another. The robotic machine consists of an arm that hovers over a wheel of vials of different liquids. In this case, the arm held a piece of glass about the size of a stick of gum on which it built the new material. The arm dipped the glass into the glue-like polymer ...

New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation

... of cough and dyspnea was 7.4% ( FU/LV arm compared to 4.5% (no grade 3, 0.1% grade 4) in the 5-FU/LV alone arm in the adjuvant colon cancer study. In this ... grade 3 and 4) in the Eloxatin(R) plus 5-FU/LV arm compared to 32% (5% grade 3 and 4) in the ...

Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents

... global contract research organization (CRO); and NovaQuest, the investment arm of Quintiles. "In this market environment, executive management ... on David Lilley Most recently, David Lilley led the Commercial arm of NovaQuest from 2005 to 2008 where he and his team executed deals to ...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

... scores of F0 to F3 at baseline demonstrated SVRs of 7.8% in the 9 mcg arm and 13.1% in the 15 mcg arm Patients maintaining full dose of INFERGEN/RBV therapy had SVRs of ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... multiple myeloma study, 25 patients (8%) in the VELCADE for Injection arm and 42 patients (13%) in the VELCADE plus DOXIL arm experienced left ventricular ejection fraction decrease (defined as ...

Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients

... Worth. "It allows us to use the current standard of care as the control arm in future clinical studies to further advance the timely clinical ... 56.9 to 60.9ml/min). The BPAR was also lowest (15.0%) in the Prograf arm when compared to the standard-dose CyA (29.0%), low-dose CyA (26.6%) or ...

Resverlogix Provides Quarterly Update

... As a result of the recently announced financing, completion of the third arm of the Phase 1b/2a trial has recommenced. Resverlogix is also pleased to ... assessment of a biomarker for Alzheimer's disease to the third and final arm of this clinical trial. "The unmet medical need of treating subjects ...

OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer

... trial will be to determine whether a greater proportion of patients in the arm treated with OGX-011 and docetaxel/prednisone experiences durable pain palliation as compared to patients in the arm treated with docetaxel/prednisone alone. It is expected that approximately ...

Dendreon Reports Fourth Quarter and 2008 Year End Financial Results

... to Dendreon a 20 percent reduction in the risk of death in the PROVENGE arm relative to placebo (Hazard Ratio= 0.80; 95% Confidence Interval ... The 20 percent reduction in the risk of death that we saw in the PROVENGE arm at our interim analysis is encouraging to us," stated Mitchell H. Gold, ...

Angiotech announces positive results from Bio-Seal(TM) clinical study

... receiving BioSeal. "We are extremely pleased that the Bio-Seal treatment arm hit the primary end point of clinical success," said Dr. William Hunter, ... 60 minutes, 24 hours and 30 days after treatment. The Bio-Seal treatment arm hit the primary end point of clinical success, absence of pneumothorax at ...

60 LED Lights Enhance Magnifying Lamp for Assembly, Engineering, Inspection or Research

... ProVue LED, with a five-inch lens and spring-balanced adjustable arm extending 33 inches, provides hands-free support for assembly and ... meticulous operations.     The sleek, lightweight arm is fully adaptable by height and angle over wide-radius work areas for ...

Resverlogix Board of Directors Update

... be reinstated. Resverlogix is also pleased to announce that the second arm of the previously announced Phase 1b/2a study has been successfully completed and the third arm will commence shortly. About RVX-208 RVX-208, a first in ...

HEALTHeCAREERS Network Pledges $15,000 to ASRT Foundation for Professional Healthcare Training

... ) As the philanthropic arm of the American Society of Radiologic Technologists, the foundation ... the ASRT Education and Research Foundation As the philanthropic arm of the ASRT, the mission of the ASRT Education and Research Foundation is ...

Dendreon Reports Third Quarter 2008 Financial Results

... Dendreon a 20 percent reduction in the risk of death in the PROVENGE arm relative to placebo (Hazard Ratio= 0.80; 95% Confidence Interval ... to see a 20 percent reduction in the risk of death in the PROVENGE arm versus placebo at the time of this analysis in a patient population that ...

Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients

... (Arm 1) and an intranasal steroid Rhinocort(R) (as a positive control, arm 2). arm 1 of the study consisted of a six-day, twice-daily intranasal ...

Monogram Announces 2008 Third Quarter Financial Results

... RNA <50 copies/mL, compared to 69% of those individuals in the control arm of the trial. In June 2008 Monogram introduced an enhanced sensitivity ... improvement in Selzentry efficacy relative to efavirenz (the control arm of the trial). In the new retrospective analysis of the MERIT trial ...

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

... that the early increase in flares was transient in this treatment arm before returning to the placebo level. The reduction of gout flares, by approximately 40%, in the every two- week dosing arm of these randomized, controlled, clinical trials is believed to be the ...

The human brain minimizes energy expenditure and integrates gravity in to the action plan

... upon the movements of living organisms. The simple observation of vertical arm movements reveals that muscle activity when moving upwards differs from ... demonstrated a necessary and sufficient condition of optimal control for arm movements which is a novelty in motor control studies. The authors ...

Denser, more powerful computer chips possible with plasmonic lenses that 'fly'

... on the lens' surface with a "flying head" that resembles the stylus on the arm of an old-fashioned LP turntable and is similar to those used in hard disk ... production. The researchers compared this flying plasmonic head to the arm and stylus of an LP turntable, with the photoresist surface spinning like ...

Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer

... (or 17 percent of evaluable patients). Fifteen patients in the FOLPI arm were not evaluable or too early to evaluate. Of 51 patients in the FOLFOX ... (or 13 percent of evaluable patients). Nine patients in the FOLFOX arm were either not evaluable or too early to evaluate. "These interim, ...

Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation

... in 2005. The Buoniconti Fund to Cure Paralysis is the fundraising arm of The Miami Project, the world's largest and most comprehensive research ... walk again. The Buoniconti Fund serves as the national fundraising arm of The Miami Project. It is designed to complement the scientific ...

Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes

... and titration of the "basal/basal plus" strategy. In the Telecare arm of the study, 50.6% of patients reached an A1C score of less than or equal ... margin=0.4%). Blood glucose values improved significantly within each arm for most pre- and post-meal timepoints. Overall, 30.7% of patients ...

Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008

... subjects that have been enrolled in a Phase II study, an additional arm of a further 100 HIV infected subjects with a previous exposure to ... of the additional funds made available under RFP-2. The enrolment in this arm has also been completed and safety data from this group will be reported ...

BIOCOM Institute Secures Non-Profit Designation and Funding

... Foundation and the San Diego Foundation, the institute is a 501 (c) (3) arm of BIOCOM, the association for the Southern California life science ... pursuing other grant opportunities as a self-sufficient science education arm of BIOCOM and has 501 (c) (3) non-profit status for tax-exempt donations. ...

Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide

... designed for patients who have difficulties using their weak or paralyzed arm and hand to perform common tasks that require grasp and release, ... fastening a belt, buttoning or sweeping. The H200 helps to restore lost arm and hand function through repetitive training with patients and may ...